According to these results, we proposed that the Twist1 protein level was fine-tuned by two signaling pathways; one was a known oncogenic signaling pathway NF-κB–Twist1, whereas the other was a new identified tumor-suppressing pathway NF-κB–miR186–Twist1. The gene discussed is TWIST1; the disease is neoplasm.